Geulah Livshits
Stock Analyst at Chardan Capital
(3.06)
# 1,286
Out of 4,944 analysts
216
Total ratings
39.25%
Success rate
1.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Buy | $9 → $10 | $3.03 | +230.03% | 14 | Aug 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $6.67 | +274.81% | 12 | Aug 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $11.00 | +445.45% | 15 | Aug 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $11 | $3.09 | +255.99% | 20 | Aug 11, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $12 → $10 | $3.81 | +162.47% | 6 | Aug 8, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $1.54 | +679.22% | 10 | Aug 8, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $20 | $2.45 | +716.33% | 14 | Aug 8, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 | $0.86 | +945.17% | 12 | Aug 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 | $57.33 | +43.03% | 15 | Aug 5, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $219 | $149.36 | +46.63% | 12 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $6.38 | +1,780.88% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 | $3.22 | +303.73% | 12 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $6.68 | +124.55% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.53 | +1,025.28% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $12 | $1.94 | +518.56% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $20 | $4.74 | +321.94% | 9 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $44.64 | +12.01% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.46 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.08 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $8.35 | +391.02% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $6.15 | +306.50% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.71 | +601.75% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $26.89 | +673.52% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.16 | +1,279.31% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.92 | +909.53% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.65 | +9.59% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.66 | +1,027.82% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $10.01 | +79.82% | 1 | Oct 27, 2020 |
Taysha Gene Therapies
Aug 12, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $3.03
Upside: +230.03%
4D Molecular Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $25
Current: $6.67
Upside: +274.81%
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $11.00
Upside: +445.45%
Rocket Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $3.09
Upside: +255.99%
Prime Medicine
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.81
Upside: +162.47%
Senti Biosciences
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $1.54
Upside: +679.22%
Iovance Biotherapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.45
Upside: +716.33%
Tenaya Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $0.86
Upside: +945.17%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $57.33
Upside: +43.03%
Krystal Biotech
Aug 5, 2025
Maintains: Buy
Price Target: $219
Current: $149.36
Upside: +46.63%
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $6.38
Upside: +1,780.88%
Jun 18, 2025
Maintains: Buy
Price Target: $13
Current: $3.22
Upside: +303.73%
May 19, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $6.68
Upside: +124.55%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.53
Upside: +1,025.28%
May 15, 2025
Maintains: Buy
Price Target: $13 → $12
Current: $1.94
Upside: +518.56%
May 13, 2025
Maintains: Buy
Price Target: $22 → $20
Current: $4.74
Upside: +321.94%
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $44.64
Upside: +12.01%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.46
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.08
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $8.35
Upside: +391.02%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $6.15
Upside: +306.50%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.71
Upside: +601.75%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $26.89
Upside: +673.52%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.16
Upside: +1,279.31%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.92
Upside: +909.53%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.65
Upside: +9.59%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.66
Upside: +1,027.82%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $10.01
Upside: +79.82%